Health & Biotechnology
Strengthening innovation, resilience and strategic cooperation between France and India
A Strategic Sector at the Core of Public Health and Industrial Innovation
Health and biotechnology stand at the intersection of science, industry and public policy. They are central to national resilience, economic performance and technological sovereignty.
The sector includes:
-
Pharmaceutical research and manufacturing
-
Biotechnology and life sciences innovation
-
Medical devices and diagnostic technologies
-
Digital health and precision medicine
-
Vaccine development and production
-
Research in genomics, immunology and advanced therapeutics
Beyond healthcare delivery, biotechnology drives industrial innovation, supports advanced manufacturing and enhances national preparedness in the face of global health challenges.
In a post-pandemic global landscape, health systems and biotech capabilities have become strategic assets.
2025–2030 Outlook: Innovation, Resilience and Industrial Scaling
Between 2025 and 2030, the sector will be shaped by major structural trends:
-
Acceleration of biotechnology research and advanced therapies
-
Integration of AI and data analytics into diagnostics and treatment
-
Strengthening of pharmaceutical supply chain resilience
-
Expansion of vaccine and biologics manufacturing capacity
-
Increased public–private investment in life sciences
Healthcare is evolving from reactive care to predictive, personalised and technology-driven systems.
10 000 billion
in USD: estimated value of the global healthcare market by 2030
+ 8 %
average annual growth of the biotech sector
Top 5
European perspective: France’s position in biotechnologies and medical research.
Top 3
Global perspective: India’s position among pharmaceutical producers.
France: Scientific Excellence and Regulatory Strength
France benefits from:
-
A strong pharmaceutical and biotechnology ecosystem
-
Globally recognised research institutions
-
Advanced regulatory frameworks for health innovation
-
Expertise in vaccine development and advanced therapeutics
-
Close integration between research, industry and public health authorities
France positions health innovation as a pillar of scientific excellence and strategic autonomy.
India: Manufacturing Scale and Health Infrastructure
India stands out through:
-
One of the world’s largest pharmaceutical manufacturing bases
-
Strong capabilities in generic medicines and vaccine production
-
Rapidly expanding healthcare infrastructure
-
A growing biotech and life sciences start-up ecosystem
-
Increasing investment in advanced research and innovation
India combines industrial scale, cost efficiency and a strong talent pool in life sciences and medical research.
Key Figures
-
Over USD 2 trillion: projected global biotechnology market by 2030
-
India among the world’s largest producers of generic medicines
-
Strong annual growth in global digital health investment
-
Rapid expansion of vaccine production capacity worldwide
Shared Strategic Priorities
France–India cooperation in health and biotechnology addresses:
-
Pharmaceutical supply chain security
-
Joint research and innovation in advanced therapies
-
Strengthening vaccine and biologics manufacturing collaboration
-
Digital health and medical data integration
-
Talent development in life sciences and biotechnology
Health cooperation extends beyond trade — it reinforces resilience, stability and long-term strategic autonomy.
Structuring a France–India Health Corridor
A structured corridor could include:
-
Joint research initiatives in biotechnology
-
Industrial partnerships in pharmaceutical manufacturing
-
Collaboration in vaccine and biologics development
-
Exchange of scientific talent and expertise
-
Institutional dialogue on regulatory harmonisation
Strategic Perspective
By 2030, health and biotechnology will remain central to economic resilience, technological leadership and national security.
The combination of France’s scientific excellence and regulatory expertise with India’s manufacturing scale and expanding innovation capacity creates a strong foundation for a forward-looking and resilient strategic partnership in health and life sciences.
Updates
